Stockreport

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under ...

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF --In preclinical studies, REX-8756 elicited complete, rapid and durable inhibition of STAT6, resulting in potent, biologic-like activity without protein degradation in [Read more]